Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Dailei Qin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7407-836X; OpenAlex author ID A5085679000. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 5 papers

Papers 11

  1. Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential against gemcitabine-resistant PDAC. Co-author DOI 10.1016/j.tranon.2024.102206↗
  2. Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of pancreatic cancer: a mendelian randomization analysis. First author DOI 10.1186/s12885-025-13824-7↗
  3. Development of a Nomogram Integrating Modified Inflammation-Based Indexes for Predicting Overall Survival in Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.2147/jir.s519779↗
  4. Enhancing pancreatic cancer treatment: the role of H101 oncolytic virus in irreversible electroporation. Co-author DOI 10.3389/fimmu.2025.1546242↗
  5. Development of a nomogram integrating immune checkpoints, fibrosis indicators, and clinicopathological characteristics to predict overall survival in pancreati… Co-author DOI 10.3389/fimmu.2025.1688440↗
  6. Blockades Adenosine Receptor 2B Suppresses Pancreatic Adenocarcinoma Progression by Inhibiting Leukemia Inhibitory Factor Secretion from Macrophages Co-author DOI 10.21203/rs.3.rs-4829619/v1↗
  7. Nomogram for predicting post-progression-free survival in patients with recurrent pancreatic ductal adenocarcinoma after radical surgery: a retrospective analy… Co-author DOI 10.3389/fmed.2024.1486750↗
  8. Prognostic effect of CD73 in pancreatic ductal adenocarcinoma for disease-free survival after radical surgery. Co-author DOI 10.1007/s00432-023-04703-4↗
  9. Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer. Co-author DOI 10.2147/jir.s404900↗
  10. Type 1 T Helper Cell-Based Molecular Subtypes and Signature Are Associated with Clinical Outcome in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fcell.2022.839893↗
  11. Sample-Specific Perturbation of Gene Interactions Identifies Pancreatic Cancer Subtypes. Co-author DOI 10.3390/ijms23094792↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zehui Yao · 9 shared papers, 2023–2025 · strength 2.23
  2. Pu Xi · 7 shared papers, 2023–2025 · strength 1.76
  3. Lingmin Jiang · 6 shared papers, 2024–2025 · strength 1.56
  4. Ran Wei · 6 shared papers, 2022–2025 · strength 1.34
  5. Shengping Li · 6 shared papers, 2022–2025 · strength 1.28
  6. Shengping Li · 3 shared papers, 2024–2025 · strength 0.77
  7. Honglu Ding · 2 shared papers, 2023 · strength 0.39
  8. Wuguo Deng · 2 shared papers, 2022 · strength 0.37
  9. Shengping Li · 1 shared paper, 2025 · strength 0.28
  10. Ran Wei · 1 shared paper, 2025 · strength 0.28
  11. Chaobin He · 1 shared paper, 2025 · strength 0.27
  12. Yize Mao · 1 shared paper, 2023 · strength 0.19
  13. Qiuxia Yang · 1 shared paper, 2023 · strength 0.19
  14. Ruiqi L. Wang · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.